According to the Zhitoong Finance APP, JiuYuan Gene (02566) fell over 5% during trading, dropping to 7.36 HKD, setting a new low since its listing, and has already fallen over 40% from the offering price of 12.42 HKD. As of the time of publication, it is down 4.38%, trading at 7.42 HKD, with a transaction volume of 14.6585 million HKD and a total market value of less than 2 billion HKD.

The prospectus shows that JiuYuan Gene was founded in 1993, headquartered in Zhejiang Province, and is a SINO BIOPHARM company with over 30 years of experience in the research, production, and commercialization of biopharmaceuticals and medical instruments; the company does not engage in genetic engineering business. It is reported that JiuYuan Gene was listed on November 28, and on the first day of trading, the stock price plummeted to 7.5 HKD, a decline of 39.61%. It closed at 7.65 HKD for the day, with a Turnover Ratio of 26.54%.

The Zhitoong Finance APP pointed out in an article titled "Speculation is rampant about artificial "intervention" in IPO multiples, what is the truth behind JiuYuan Gene (02566) falling sharply on the first day?" that the stock price performance of JiuYuan Gene is in stark contrast to its IPO Subscription enthusiasm. Due to the public offering portion having a subscription multiple exceeding 100 times, triggering a mechanism to return shares, JiuYuan Gene has reallocated 18.1594 million shares from international offering to public offering. This has objectively increased the shares in retail investors' hands significantly, incurring greater losses amidst the drop in stock price. There have been various voices in the market questioning that the high multiple subscription for JiuYuan Gene in the public offering is a man-made "lemming effect." The Zhitoong Finance APP cannot verify the authenticity of the rumors, and like many investors, looks forward to a clarification from the company.